Wedbush Downgrades Meridian Biosciences (VIVO) to Underperform as Competitor Gains Momentum
Tweet Send to a Friend
Wedbush downgraded Meridian Biosciences (NASDAQ: VIVO) from Neutral to Underperform with a price target of $17.00 on poor risk/reward.
This article: 210 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 210 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
